{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:40:52Z","timestamp":1793410852275,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in humans. Results from mouse models of Alzheimer\u2019s disease have shown beneficial effects of rapamycin, including preventing or reversing cognitive deficits, reducing amyloid oligomers and tauopathies and normalizing synaptic plasticity and cerebral glucose uptake. The \u201cEvaluating Rapamycin Treatment in Alzheimer\u2019s Disease using Positron Emission Tomography\u201d (ERAP) trial aims to test if these results translate to humans through evaluating the change in cerebral glucose uptake following six months of rapamycin treatment in participants with early-stage Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      ERAP is a six-month-long, single-arm, open-label, phase IIa biomarker-driven study evaluating if the drug rapamycin can be repurposed to treat Alzheimer\u2019s disease. Fifteen patients will be included and treated with a weekly dose of 7\u00a0mg rapamycin for six months. The primary endpoint will be change in cerebral glucose uptake, measured using [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG positron emission tomography. Secondary endpoints include changes in cognitive measures, markers in cerebrospinal fluid as well as cerebral blood flow measured using magnetic resonance imaging. As exploratory outcomes, the study will assess change in multiple age-related pathological processes, such as periodontal inflammation, retinal degeneration, bone mineral density loss, atherosclerosis and decreased cardiac function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The ERAP study is a clinical trial using in vivo imaging biomarkers to assess the repurposing of rapamycin for the treatment of Alzheimer\u2019s disease. If successful, the study would provide a strong rationale for large-scale evaluation of mTOR-inhibitors as a potential disease-modifying treatment in Alzheimer\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov ID NCT06022068, date of registration 2023\u201308-30.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-024-03596-1","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T02:01:50Z","timestamp":1712196110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Evaluating the effect of rapamycin treatment in Alzheimer\u2019s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Jonas E.","family":"Svensson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune","family":"Brautaset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder","family":"S\u00f6rensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marlevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens","family":"Spin-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Hagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton Forsberg","family":"Mor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Kivipelto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Plav\u00e9n-Sigray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"3596_CR1","doi-asserted-by":"publisher","first-page":"n156","DOI":"10.1136\/bmj.n156","volume":"372","author":"SF Ackley","year":"2021","unstructured":"Ackley SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, Gold AL, Manly JJ, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372:n156.","journal-title":"BMJ."},{"issue":"3","key":"3596_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41582-022-00768-w","volume":"19","author":"M Thambisetty","year":"2023","unstructured":"Thambisetty M, Howard R. Lecanemab trial in AD brings hope but requires greater clarity. Nat Rev Neurol. 2023;19(3):132\u20133.","journal-title":"Nat Rev Neurol"},{"key":"3596_CR3","volume-title":"World Alzheimer report 2015 - The global impact of dementia. An analysis of prevalence, incidence, cost and trends","author":"MJ Prince","year":"2015","unstructured":"Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu YT, Prina M. World Alzheimer report 2015 - The global impact of dementia. An analysis of prevalence, incidence, cost and trends. London: Alzheimer\u2019s Disease International; 2015."},{"issue":"2","key":"3596_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"C Qiu","year":"2009","unstructured":"Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111\u201328.","journal-title":"Dialogues Clin Neurosci"},{"key":"3596_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ebiom.2016.11.038","volume":"21","author":"NL Nadon","year":"2017","unstructured":"Nadon NL, Strong R, Miller RA, Harrison DE. NIA interventions testing program: investigating putative aging intervention agents in a genetically heterogeneous mouse model. EBioMedicine. 2017;21:3\u20134.","journal-title":"EBioMedicine"},{"issue":"476","key":"3596_CR6","doi-asserted-by":"publisher","first-page":"eaar428","DOI":"10.1126\/scitranslmed.aar4289","volume":"11","author":"M Kaeberlein","year":"2019","unstructured":"Kaeberlein M, Galvan V. Rapamycin and Alzheimer\u2019s disease: Time for a clinical trial? Sci Transl Med. 2019;11(476):eaar428.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3596_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13024-021-00428-5","volume":"16","author":"H Querfurth","year":"2021","unstructured":"Querfurth H, Lee HK. Mammalian\/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration. Mol Neurodegener. 2021;16(1):44.","journal-title":"Mol Neurodegener."},{"key":"3596_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s43587-023-00416-y","volume":"3","author":"JB Mannick","year":"2023","unstructured":"Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat Aging. 2023;3:642\u201360.","journal-title":"Nat Aging"},{"key":"3596_CR9","first-page":"107","volume-title":"Interdisciplinary Topics in Gerontology and Geriatrics","author":"SC Johnson","year":"2015","unstructured":"Johnson SC, Sangesland M, Kaeberlein M, Rabinovitch PS. Modulating mTOR in Aging and Health. In: Interdisciplinary Topics in Gerontology and Geriatrics. 2015. p. 107\u201327."},{"key":"3596_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11357-017-9994-6","volume":"39","author":"JY An","year":"2017","unstructured":"An JY, Quarles EK, Mekvanich S, Kang A, Liu A, Santos D, et al. Rapamycin treatment attenuates age-associated periodontitis in mice. Geroscience. 2017;39:457\u201363.","journal-title":"Geroscience"},{"issue":"52","key":"3596_CR11","doi-asserted-by":"publisher","first-page":"33619","DOI":"10.1073\/pnas.2014213117","volume":"117","author":"JM Harder","year":"2020","unstructured":"Harder JM, Guymer C, Wood JPM, Daskalaki E, Chidlow G, Zhang C, et al. Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin. Proc Natl Acad Sci. 2020;117(52):33619\u201327.","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"3596_CR12","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1248\/bpb.b17-00475","volume":"40","author":"T Nakahara","year":"2017","unstructured":"Nakahara T, Morita A, Yagasaki R, Mori A, Sakamoto K. Mammalian target of Rapamycin (mTOR) as a potential therapeutic target in pathological ocular angiogenesis. Biol Pharm Bull. 2017;40(12):2045\u20139.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"3596_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14728222.2020.1723079","volume":"24","author":"DG de Munck","year":"2020","unstructured":"de Munck DG, de Meyer GRY, Martinet W. Autophagy as an emerging therapeutic target for age-related vascular pathologies. Expert Opin Ther Targets. 2020;24(2):131\u201345.","journal-title":"Expert Opin Ther Targets"},{"issue":"6","key":"3596_CR14","first-page":"846","volume":"11","author":"AL Silva","year":"2018","unstructured":"Silva AL, Fusco DR, Nga HS, Takase HM, Bravin AM, Contti MM, et al. Effect of sirolimus on carotid atherosclerosis in kidney transplant recipients: data derived from a prospective randomized controlled trial. Clin Kidney J. 2018;11(6):846\u201352.","journal-title":"Clin Kidney J"},{"issue":"2","key":"3596_CR15","doi-asserted-by":"publisher","first-page":"e13086","DOI":"10.1111\/acel.13086","volume":"19","author":"E Quarles","year":"2020","unstructured":"Quarles E, Basisty N, Chiao YA, Merrihew G, Gu H, Sweetwyne MT, et al. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging Cell. 2020;19(2):e13086.","journal-title":"Aging Cell"},{"issue":"2","key":"3596_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11357-017-9972-z","volume":"39","author":"SR Urfer","year":"2017","unstructured":"Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. Geroscience. 2017;39(2):117\u201327.","journal-title":"Geroscience"},{"issue":"3","key":"3596_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00198-015-3325-5","volume":"27","author":"D Luo","year":"2016","unstructured":"Luo D, Ren H, Li T, Lian K, Lin D. Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. Osteoporosis Int. 2016;27(3):1093\u2013101.","journal-title":"Osteoporosis Int"},{"key":"3596_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bone.2018.12.019","volume":"121","author":"J Wu","year":"2019","unstructured":"Wu J, Wang A, Wang X, Li G, Jia P, Shen G, et al. Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis. Bone. 2019;121:16\u201328.","journal-title":"Bone"},{"issue":"6","key":"3596_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/1947-2714.159325","volume":"7","author":"K Abbayya","year":"2015","unstructured":"Abbayya K, Chidambar YS, Naduwinmani S, Puthanakar N. Association between periodontitis and alzheimer\u2032s disease. N Am J Med Sci. 2015;7(6):241\u20136.","journal-title":"N Am J Med Sci"},{"key":"3596_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnagi.2022.912709","volume":"14","author":"H Wu","year":"2022","unstructured":"Wu H, Qiu W, Zhu X, Li X, Xie Z, Carreras I, et al. The periodontal pathogen fusobacterium nucleatum exacerbates Alzheimer\u2019s pathogenesis via specific pathways. Front Aging Neurosci. 2022;14:14.","journal-title":"Front Aging Neurosci."},{"key":"3596_CR21","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s11357-020-00252-7","volume":"42","author":"C Czak\u00f3","year":"2020","unstructured":"Czak\u00f3 C, Kov\u00e1cs T, Ungvari Z, Csiszar A, Yabluchanskiy A, Conley S, et al. Retinal biomarkers for Alzheimer\u2019s disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. Geroscience. 2020;42:1499\u2013525.","journal-title":"Geroscience"},{"issue":"10","key":"3596_CR22","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaneurol.2018.1563","volume":"75","author":"U Mutlu","year":"2018","unstructured":"Mutlu U, Colijn JM, Ikram MA, Bonnemaijer PWM, Licher S, Wolters FJ, et al. Association of retinal neurodegeneration on optical coherence tomography with dementia: a population-based study. JAMA Neurol. 2018;75(10):1256\u201363.","journal-title":"JAMA Neurol"},{"key":"3596_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/2617970","volume":"2020","author":"G Tini","year":"2020","unstructured":"Tini G, Scagliola R, Monacelli F, La Malfa G, Porto I, Brunelli C, et al. Alzheimer\u2019s disease and cardiovascular disease: a particular association. Cardiol Res Pract. 2020;2020:1\u201310.","journal-title":"Cardiol Res Pract"},{"issue":"9","key":"3596_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/archinte.166.9.1003","volume":"166","author":"C Qiu","year":"2006","unstructured":"Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and alzheimer disease. Arch Intern Med. 2006;166(9):1003\u20138.","journal-title":"Arch Intern Med"},{"issue":"2","key":"3596_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/nmt.14.53","volume":"5","author":"TM Hughes","year":"2015","unstructured":"Hughes TM, Craft S, Lopez OL. Review of \u2018the potential role of arterial stiffness in the pathogenesis of Alzheimer\u2019s disease.\u2019 Neurodegener Dis Manag. 2015;5(2):121\u201335.","journal-title":"Neurodegener Dis Manag"},{"issue":"1\u20132","key":"3596_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jns.2012.07.032","volume":"322","author":"RN Kalaria","year":"2012","unstructured":"Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012;322(1\u20132):141\u20137.","journal-title":"J Neurol Sci"},{"issue":"9","key":"3596_CR27","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.clnu.2019.12.014","volume":"39","author":"TC Peng","year":"2020","unstructured":"Peng TC, Chen WL, Wu LW, Chang YW, Kao TW. Sarcopenia and cognitive impairment: a systematic review and meta-analysis. Clin Nutr. 2020;39(9):2695\u2013701.","journal-title":"Clin Nutr"},{"key":"3596_CR28","doi-asserted-by":"publisher","first-page":"104268","DOI":"10.1016\/j.archger.2020.104268","volume":"92","author":"SJ Waite","year":"2021","unstructured":"Waite SJ, Maitland S, Thomas A, Yarnall AJ. Sarcopenia and frailty in individuals with dementia: a systematic review. Arch Gerontol Geriatr. 2021;92:104268.","journal-title":"Arch Gerontol Geriatr."},{"key":"3596_CR29","doi-asserted-by":"crossref","unstructured":"Lary CW, Ghatan S, Gerety M, Hinton A, Nagarajan A, Rosen C, et al. Bone mineral density and the risk of incident dementia: a meta-analysis. J Am Geriatr Soc. 2023;72(1):194\u2013200.","DOI":"10.1111\/jgs.18638"},{"issue":"11","key":"3596_CR30","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/jbmr.4402","volume":"36","author":"D Bliuc","year":"2021","unstructured":"Bliuc D, Tran T, Adachi JD, Atkins GJ, Berger C, van den Bergh J, et al. Cognitive decline is associated with an accelerated rate of bone loss and increased fracture risk in women: a prospective study from the Canadian Multicentre osteoporosis study. J Bone Miner Res. 2021;36(11):2106\u201315.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"3596_CR31","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11914-022-00736-9","volume":"20","author":"SX Sui","year":"2022","unstructured":"Sui SX, Balanta-Melo J, Pasco JA, Plotkin LI. Musculoskeletal deficits and cognitive impairment: epidemiological evidence and biological mechanisms. Curr Osteoporos Rep. 2022;20(5):260\u201372.","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"3596_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1152\/ajpheart.00570.2017","volume":"314","author":"CE Van Skike","year":"2018","unstructured":"Van Skike CE, Jahrling JB, Olson AB, Sayre NL, Hussong SA, Ungvari Z, et al. Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer\u2019s disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol. 2018;314(4):693\u2013703.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"3596_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/0271678X15621575","volume":"37","author":"AL Lin","year":"2017","unstructured":"Lin AL, Jahrling JB, Zhang W, DeRosa N, Bakshi V, Romero P, et al. Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2017;37(1):217\u201326.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3596_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2014.05.032","volume":"85","author":"T Jiang","year":"2014","unstructured":"Jiang T, Yu JT, Zhu XC, Zhang QQ, Cao L, Wang HF, et al. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology. 2014;85:121\u201330.","journal-title":"Neuropharmacology"},{"issue":"17","key":"3596_CR35","doi-asserted-by":"publisher","first-page":"13107","DOI":"10.1074\/jbc.M110.100420","volume":"285","author":"A Caccamo","year":"2010","unstructured":"Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of Rapamycin (mTOR), amyloid-beta and tau: effects on cognitive impairments. J Biol Chem. 2010;285(17):13107\u201320.","journal-title":"J Biol Chem"},{"issue":"10","key":"3596_CR36","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/gerona\/glab142","volume":"76","author":"H Wang","year":"2021","unstructured":"Wang H, Fu J, Xu X, Yang Z, Zhang T. Rapamycin activates Mitophagy and alleviates cognitive and synaptic plasticity deficits in a mouse model of Alzheimer\u2019s Disease. J Gerontol. 2021;76(10):1707\u201313.","journal-title":"J Gerontol"},{"issue":"1","key":"3596_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/0271678X17705973","volume":"38","author":"JB Jahrling","year":"2018","unstructured":"Jahrling JB, Lin AL, DeRosa N, Hussong SA, Van Skike CE, Girotti M, et al. mTOR drives cerebral blood flow and memory deficits in LDLR\u2013\/\u2013 mice modeling atherosclerosis and vascular cognitive impairment. J Cereb Blood Flow Metab. 2018;38(1):58\u201374.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"19","key":"3596_CR38","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1523\/JNEUROSCI.2144-20.2021","volume":"41","author":"CE Van Skike","year":"2021","unstructured":"Van Skike CE, Hussong SA, Hernandez SF, Banh AQ, DeRosa N, Galvan V. mTOR attenuation with rapamycin reverses neurovascular uncoupling and memory deficits in mice modeling Alzheimer\u2019s disease. J Neurosci. 2021;41(19):4305\u201320.","journal-title":"J Neurosci"},{"issue":"4","key":"3596_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.pneurobio.2010.11.005","volume":"95","author":"H Hampel","year":"2011","unstructured":"Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, et al. Biomarkers for Alzheimer\u2019s disease therapeutic trials. Prog Neurobiol. 2011;95(4):579\u201393.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"3596_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/bmm.12.51","volume":"6","author":"K Herholz","year":"2012","unstructured":"Herholz K. Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer\u2019s disease. Biomark Med. 2012;6(4):431\u20139.","journal-title":"Biomark Med"},{"issue":"19","key":"3596_CR41","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1212\/WNL.0000000000201043","volume":"99","author":"A Rosenberg","year":"2022","unstructured":"Rosenberg A, \u00d6hlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryd\u00e9n M, et al. \u03b2-Amyloid, Tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. Neurology. 2022;99(19):2102\u201313.","journal-title":"Neurology"},{"issue":"4","key":"3596_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3596_CR43","unstructured":"Pfizer. Sirolimus (RAPAMUNE)[package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021083s059,021110s076lbl.pdf. Accessed 29 Nov 2023."},{"issue":"2","key":"3596_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","volume":"4","author":"K Sankhala","year":"2009","unstructured":"Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009;4(2):135\u201342.","journal-title":"Target Oncol"},{"key":"3596_CR45","doi-asserted-by":"crossref","unstructured":"Lamming DW. Rapamycin and rapalogs. In: Anti-aging pharmacology. Academic Press; Cambridge, Massachusetts: 2023. p. 89\u2013118.","DOI":"10.1016\/B978-0-12-823679-6.00002-3"},{"issue":"4","key":"3596_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1046\/j.1365-3083.1996.d01-52.x","volume":"43","author":"BR Yacyshyn","year":"1996","unstructured":"Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM. Inhibition by rapamycin of p-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol. 1996;43(4):449\u201355.","journal-title":"Scand J Immunol"},{"issue":"1\u20133","key":"3596_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1\u20133):3\u201326.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"3596_CR48","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","volume":"20","author":"DJAR Moes","year":"2015","unstructured":"Moes DJAR, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20(10):1243\u20139.","journal-title":"Drug Discov Today"},{"issue":"6","key":"3596_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/sj.bjp.0704142","volume":"133","author":"N Serkova","year":"2001","unstructured":"Serkova N, Jacobsen W, Niemann CU, Litt L, Benet LZ, Leibfritz D, et al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. 2001;133(6):875\u201385.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3596_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.neuro.2010.10.006","volume":"32","author":"S Gottschalk","year":"2011","unstructured":"Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011;32(1):50\u20137.","journal-title":"Neurotoxicology"},{"key":"3596_CR51","doi-asserted-by":"crossref","unstructured":"Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021;123:50\u201366.","DOI":"10.1016\/j.pediatrneurol.2021.07.011"},{"key":"3596_CR52","doi-asserted-by":"publisher","first-page":"3786083","DOI":"10.1155\/2018\/3786083","volume":"2018","author":"J Jiang","year":"2018","unstructured":"Jiang J, Sun Y, Zhou H, Li S, Huang Z, Wu P, et al. Study of the influence of age in 18F-FDG PET images using a data-driven approach and its evaluation in Alzheimer\u2019s disease. Contrast Media Mol Imaging. 2018;2018:3786083.","journal-title":"Contrast Media Mol Imaging."},{"issue":"7","key":"3596_CR53","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207\u201318.","journal-title":"Neurobiol Aging"},{"issue":"11","key":"3596_CR54","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19(11):951\u201362.","journal-title":"Lancet Neurol"},{"issue":"5","key":"3596_CR55","first-page":"269","volume":"6","author":"D F\u00e4llmar","year":"2016","unstructured":"F\u00e4llmar D, Lilja J, Kilander L, Danfors T, Lubberink M, Larsson EM, et al. Validation of true low-dose 18F-FDG PET of the brain. Am J Nucl Med Mol Imaging. 2016;6(5):269\u201376.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"3596_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0193(200005)10:1<1::AID-HBM10>3.0.CO;2-O","volume":"10","author":"SM Schaefer","year":"2000","unstructured":"Schaefer SM, Abercrombie HC, Lindgren KA, Larson CL, Ward RT, Oakes TR, et al. Six-month test-retest reliability of MRI-defined PET measures of regional cerebral glucose metabolic rate in selected subcortical structures. Hum Brain Mapp. 2000;10(1):1\u20139.","journal-title":"Hum Brain Mapp"},{"key":"3596_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, M\u00f8ller A, Hansen SB, Vang K, et al. In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108.","journal-title":"Front Aging Neurosci."},{"issue":"5","key":"3596_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ana.21345","volume":"63","author":"A Kadir","year":"2008","unstructured":"Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer\u2019s disease. Ann Neurol. 2008;63(5):621\u201331.","journal-title":"Ann Neurol"},{"issue":"1","key":"3596_CR59","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement. 2022;8(1):e12295.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"3596_CR60","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"3596_CR61","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2741\/s310","volume":"4","author":"S Oddo","year":"2012","unstructured":"Oddo S. The role of mTOR signaling in Alzheimer disease. Front Biosci. 2012;4:941.","journal-title":"Front Biosci"},{"key":"3596_CR62","doi-asserted-by":"crossref","unstructured":"Karabiyik C, Frake RA, Park SJ, Pavel M, Rubinsztein DC. Autophagy in ageing and ageing-related neurodegenerative diseases. Ageing Neurodegener Dis. 2021;1(2).","DOI":"10.20517\/and.2021.05"},{"issue":"12","key":"3596_CR63","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"Z Bv","year":"2011","unstructured":"Bv Z. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723\u201338.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"3596_CR64","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.bbadis.2015.11.010","volume":"1862","author":"V Galvan","year":"2016","unstructured":"Galvan V, Hart MJ. Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer\u2019s disease. Biochim et Biophys Acta (BBA) - Mol Basis Disease. 2016;1862(5):992\u20131007.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Basis Disease"},{"issue":"1","key":"3596_CR65","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1038\/ncomms11934","volume":"7","author":"Y Iturria-Medina","year":"2016","unstructured":"Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-P\u00e9rez JM, Evans AC, Weiner MW, et al. Early role of vascular dysregulation on late-onset Alzheimer\u2019s disease based on multifactorial data-driven analysis. Nat Commun. 2016;7(1):11934.","journal-title":"Nat Commun"},{"issue":"3","key":"3596_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000485381","volume":"64","author":"CE van Skike","year":"2018","unstructured":"van Skike CE, Galvan VA. A rerfect sTORm: The role of the mammalian target of rapamycin (mTOR) in cerebrovascular dysfunction of Alzheimer\u2019s disease: a mini-review. Gerontology. 2018;64(3):205\u201311.","journal-title":"Gerontology"},{"issue":"1","key":"3596_CR67","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2018;4(1):575\u201390.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"14","key":"3596_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144216","volume":"11","author":"S Wolf","year":"2022","unstructured":"Wolf S, Hoffmann VS, Sommer F, Schrempf M, Li M, Ryll M, et al. Effect of Sirolimus vs. Everolimus on CMV-Infections after kidney transplantation\u2014a network meta-analysis. J Clin Med. 2022;11(14): 4216.","journal-title":"J Clin Med"},{"key":"3596_CR69","doi-asserted-by":"crossref","unstructured":"Mannick J, Giuseppe DG, Maria L, VN M, Jens P, Baisong H et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268).","DOI":"10.1126\/scitranslmed.3009892"},{"issue":"2","key":"3596_CR70","doi-asserted-by":"publisher","first-page":"fcaa112","DOI":"10.1093\/braincomms\/fcaa112","volume":"2","author":"A Faridar","year":"2020","unstructured":"Faridar A, Thome AD, Zhao W, Thonhoff JR, Beers DR, Pascual B, et al. Restoring regulatory T-cell dysfunction in Alzheimer\u2019s disease through ex vivo expansion. Brain Commun. 2020;2(2):fcaa112.","journal-title":"Brain Commun"},{"key":"3596_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exger.2014.12.002","volume":"68","author":"A Richardson","year":"2015","unstructured":"Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to therapies for Alzheimer\u2019s disease: The rapamycin story. Exp Gerontol. 2015;68:51\u20138.","journal-title":"Exp Gerontol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-024-03596-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-024-03596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T03:05:04Z","timestamp":1712199904000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-024-03596-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3596"],"URL":"https:\/\/doi.org\/10.1186\/s12883-024-03596-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and relevant documents were approved following review by the Swedish Medical Products Agency (L\u00e4kemedelsverket, number: 5.1-2023-8283), and the Swedish Ethical Review Authority (Etikpr\u00f6vningsmyndigheten, number: 2023-03075-02 and 2023-00611-01), EudraCT number: 2023-000127-36. The trial has been registered at ClinicalTrials.gov (NCT06022068, first released on August 30, 2023). Prior to study enrolment, informed consent will be obtained from each participant and their study partner.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}